MAYNE Pharma has
announced the US Food and
Drug Administration approval of
enteric coated antibacterial Doryx
MPC (doxycycline hyclate delayed
release tablets).
A tetracycline-class product, one
of the common uses of Doryx is in
severe acne treatment.
It orginally started life as a lower
urinary tract generic therapy
owned by Pfizer who marketed
the same product as Vibramycin
primarily for respiratory conditions.
The potential for Doryx in the US
is highlighted by the fact that acne
is the most prevalent skin disease
affecting around 45 million people
of all ages, Mayne has said.The above article was sent to subscribers in Pharmacy Daily's issue from 25 May 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 May 16
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.